Literature DB >> 16679790

Deep lamellar keratoplasty in the treatment of keratoconus.

Nima Pakrou1, Shirley Fung, Dinesh Selva, Mark Chehade, Igal Leibovitch.   

Abstract

PURPOSE: To present our experience with a series of patients treated with deep lamellar keratoplasty (DLK) for keratoconus (KC).
DESIGN: A single surgeon, prospective, consecutive series.
METHOD: The study included all patients with KC who underwent DLK between March 1999 and November 2003 at the Royal Adelaide Hospital. The parameters evaluated included patients' demographics, pre- and post-operative best corrected visual acuities, post-operative keratometry, and intra- and post-operative complications.
RESULTS: There were 22 patients (23 eyes); 10 females and 12 males, with a mean age of 35 +/- 13 years (median, 33.5; range, 17-73). The median follow-up period was 13 months (range 7-38). In 89% (16/18) of eyes which underwent DLK, and in which a visual acuity could be obtained, a best corrected visual acuity of at least 6/12 was recorded. There were two episodes of Descemet's membrane perforation (8.7%), in which the procedure was converted to penetrating keratoplasty without complications. One patient developed a double anterior chamber, which resolved spontaneously without consequences.
CONCLUSION: The visual outcomes and complication rates seen in our series are comparable to the recent published literature. Hence DLK can be considered as a suitable alternative to penetrating keratoplasty for the surgical treatment of KC.

Entities:  

Mesh:

Year:  2006        PMID: 16679790     DOI: 10.1159/000091759

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

Review 1.  [Keratoplasty: laminate or penetrate? Part 2: lamellar keratoplasty].

Authors:  P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2009-07       Impact factor: 1.059

2.  Intraoperative perforation of Descemet's membrane during "big bubble" deep anterior lamellar keratoplasty.

Authors:  Vishal Jhanji; Namrata Sharma; Rasik B Vajpayee
Journal:  Int Ophthalmol       Date:  2009-12-24       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.